Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients

Ozdemir N., AKSOY S., Sendur M., Akinci M., Yazici O., Budakoglu B., ...Daha Fazla

Journal of B.U.ON., cilt.18, sa.4, ss.831-837, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 4
  • Basım Tarihi: 2013
  • Dergi Adı: Journal of B.U.ON.
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.831-837
  • Anahtar Kelimeler: breast cancer, capecitabine, cisplatin, HER-2, metastatic, PHASE-II, CANCER PATIENTS, PLUS CAPECITABINE, MITOMYCIN-C, COMBINATION, CISPLATIN, CHEMOTHERAPY, VINORELBINE, PACLITAXEL, EPIRUBICIN
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Purpose: To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (Cap Cisp) in anthra-cycline-and taxane-pretreated HER-2 negative metastatic breast carcinoma (MBC) female patients. Methods: Patients with HER-2 negative MBC pretreated with anthracycline and taxane and who were then treated with CapCisp combination were retrospectively evaluated. All patients received Cap 1000 mg/m2 on days 1-14, and Cisp 60 mg/m2 on day 1, repeated every 3 weeks. In case of disease control without severe toxicity, single agent Cap was continued until progression or unacceptable toxicities after Cisp cessation. Results: Sixty-four MBC patients with median age 43 years (range 20-66) were included the study. Infiltrative ductal carcinoma prevailed (85.9%). Ten percent of the patients had grade I, 42% grade II, and 48.0% grade III tumors. Estrogen receptor (ER) and progesterone receptor (PR) were positive in 48.4 and 51.6% of the patients, respectively. Twenty-eight percent of the patients had triple negative tumors. Almost the entire patient group had this regimen as a third-line treatment. The median combination chemotherapy cycles were 6 (range 2-8). Twenty-seven non-progressive patients continued treatment with single-agent Cap. Median single-agent Cap cycles after the combination chemotherapy were 4 (range 1-38). Disease control rate was 81.3% (complete response 6.3%; partial response 48.4%, stable disease 26.6%, progressive disease 18.8%). Median follow-up time was 10.6 months. Median time to disease progression was 7 months, median overall survival (OS) was 17 months (95% CI, 6.9-16.1) measured from the start of CapCisp chemotherapy. There were no treatment-related deaths. The most frequent grade 3-4 toxicities were neutro-penia (8.1%), nausea - vomiting (7.8%) and thrombocyto-penia (6.3%). Conclusion: CapCisp doublet has an encouraging antitu-mor activity with acceptable and manageable toxicity in anthracycline- and taxane-pretreated HER-2 negative met-astatic breast carcinoma patients.